Cohort study reports disease-modifying therapy expenditures and safety outcomes of alemtuzumab in relapsing multiple sclerosis, highlighting single-center health economic impacts.
To describe DMT cost expenditure and clinical/safety outcomes in a single MS center of an Alemtuzumab cohort of 300 relapsing patients.
No takes yet. Share an insight, caveat, or question.
LaGanke et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: